Not every day I am honoured by working together with two fantastic teams who's articles independently got accepted to be published in the same issue of JAMA!

How COVID broke the evidence pipeline. The pandemic stress-tested the way the world produces evidence — and revealed all the flaws nature.com/articles/d4158…

To meet the urgent demand for effective therapies for #COVID19, FDA has worked with clinical trial experts to rapidly advance best practices in the design and execution of clinical trials.

EU SolidAct, a new platform trial for emerging pandemics, today starts testing new drugs for severe COVID-19, aiming to improve treatment options and to strengthen European pandemic preparedness bit.ly/EU_SolidAct / EU-SolidAct / ECRIN / Inserm / EU Science & Innovation 🇪🇺

Happy to inform that the two first patients are included, the first at the world's northernmost university hospital UNN with PI A Kildal and the second in @SykehusVestfold with PI Asgeir Johannessen! EU Science & Innovation 🇪🇺 / ECRIN / Oslounivsykehus / Inserm

Finally the Nor-Solidarity paper has been published in Annals of Int Med. It has really been a remarkable journey since the first hectic weeks after the virus hit Norway! Proud to have been part of this major effort.

Gilead's Veklury shows 'no antiviral effects,' small Norwegian WHO study says as company stands by COVID med fiercepharma.com/pharma/gilead-…

Viktig kommentar! Reglementet, eller tolkningen av det er for strengt, spesielt definisjonen av anonyme data.

Important comment from Giske Ursin and Heidi Beate Bentzen The regulatory hurdles are too restrictive, we need the ability to perform research for the greater good! rdcu.be/crVvf

God og kunnskapsbasert informasjon i Aftenposten i dag! aftenposten.no/meninger/kroni…

God kommentar om styrkeberegning for observasjonelle data. Ikke gjør det! Hvis problemstillingen er interessant er det mye bedre å bare gjøre det og publisere slik at resultatene kan inngå i en ev. meta-analyse.

A new RCT on vaccine treatment on patients with tuberculosis carried through at Oslounivsykehus nature.com/articles/s4146…

Happy to have been part of this great trial!

Nice article in Aftenposten on treatment options for C19 and the ⁦EU-SolidAct⁩ trial with ⁦Aleksander Holten⁩ aftenposten.no/norge/i/8Q7RnQ…

Next time you do a proportional hazard model analysis, give a thought to the man who invented it.

BerGenBio and Oslounivsykehus announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients eu-response.eu/bergenbio-and-… EU Science & Innovation 🇪🇺/Inserm/ECRIN

In double-blind RCT, ivermectin that was administered within 7 days after Covid-19 symptom onset was shown not to be of any clinical benefit. nej.md/3LtHLyh

Happy to have been involved in this trial! Early food intervention and skin emollients to prevent food allergy in young children (#PreventADALL): a factorial, multicentre, cluster-randomised trial thelancet.com/journals/lance…

Read our experiences as an academic sponsor with the new regulatory and ethical application portal in Europe. EU-SolidAct Oslounivsykehus Oslo Centre for Biostatistics and Epidemiology

Exciting day at the EMA where we shared our experiences with running Covid-19 trials with the Director-General of Health, and Research, in a workshop for pandemic preparedness.